A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Trial Profile

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Hepatocyte growth factor gene therapy (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors ViroMed
  • Most Recent Events

    • 09 Feb 2017 According to VM BioPharma media release, clinical safety and tolerability data was published online at the scientific journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and will be published in a future print issue of the journal.
    • 17 May 2016 According to a ViroMed media release, the US FDA granted fast track designation to VM202 for the potential treatment of ALS. ViroMed expects the publication of data from this trial in H2 2016.
    • 22 Jan 2016 Status changed from active, no longer recruiting to completed, according to a ViroMed Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top